Loading…
Biotech developing treatments for genetic diseases, led by Attruby for transthyretin amyloid cardiomyopathy, a rare heart condition.
Biotech developing treatments for genetic diseases, led by Attruby for transthyretin amyloid cardiomyopathy, a rare heart condition.
Sells Attruby itself in the US, mostly through specialty pharmacies, and has licensed it in Europe to Bayer, which sells it there and pays BridgeBio royalties and milestone payments. The company was built as a holding of separate drug-development subsidiaries, and Attruby came from one of them, Eidos, which it bought in full in 2021.
Moat: narrow (IP / patents, regulatory licence). A patent-protected small-molecule stabilizer competing in a newly established, high-value rare cardiac disease category.
Headquarters: Palo Alto, California, US · Founded: 2015 · Employees: 839
Size BridgeBio Pharma (BBIO) is a United States Health Care company (Biotechnology) with a market value of $14.5B, the 616th largest of 3,117 United States companies the cockpit tracks. Shares closed at $74.29 on 6 Nov 2026.
Performance Over six months the shares gained 10.2%, against +14.7% for the median peer and -1.1% for the United States market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 167.3% over the last twelve months (peer median +20.8%); the operating margin is -37.3% (peer median 17.3%).
Valuation It trades at 18.3× enterprise value to sales against a peer median of 7.7× (3rd most expensive of 19).
Capital Return on invested capital runs 32.7 points below its cost of capital (8.9% WACC).
Credit BridgeBio Pharma has 4 bonds outstanding ($2.50B).
Short interest Short interest is 10.2% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $946M | $502M | $222M | $9.30M | $77.6M |
| Revenue growth | — | +126% | +2,285% | -88% | — |
| Gross profit | $890M | $478M | $214M | $2.76M | $69.8M |
| EBITDA | -$348M | -$497M | -$571M | -$593M | -$462M |
| Net income | -$566M | -$725M | -$536M | -$643M | -$481M |
| Free cash flow | -$370M | -$447M | -$522M | -$529M | -$426M |
| Capital expenditure | $835,000 | $9.59M | $8.91M | $1.31M | $6.32M |
| Total debt | $3.41B | $2.73B | $2.21B | $1.74B | $1.72B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| BridgeBio Pharma BBIO | $14.5B | +10% | +167% | -37% | 18.3× | n/a |
| Pfizer PFE | $168B | +14% | +1% | 26% | 3.4× | -4.3% |
| Alnylam Pharmaceuticals ALNY | $20.9B | -47% | +56% | 20% | 4.0× | 0.9% |
| Ionis Pharmaceuticals IONS | $6.55B | -48% | -7% | -68% | 7.7× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BBIO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.2% | -4.9% | 4th highest of 21 |
| 6-month return | +10.2% | +14.7% | 11th highest of 21 |
| Distance from 52-week high | -20.5% | -22.0% | 8th highest of 21 |
| Revenue growth (TTM) | +167.3% | +20.8% | highest of 19 |
| Operating margin | -37.3% | 17.3% | 3rd lowest of 19 |
| EV / Sales | 18.3× | 7.7× | 3rd most expensive of 19 |
| ROIC minus cost of capital | -32.7 pp | -0.3 pp | 7th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma BBIO | United States | $14.5B | +10% | +167% | -37% | 18.3× | n/a | n/a |
| Summit Therapeutics SMMT | United States | $13.1B | -10% | n/a | n/a | n/a | n/a | n/a |
| Elanco Animal Health ELAN | United States | $12.9B | +9% | +12% | 7% | 3.2× | 34.8% | +7.6% |
| Neurocrine Biosciences NBIX | United States | $16.7B | +8% | +38% | 25% | 4.4× | -1.7% | +22.3% |
| Cspc Pharma 1093.HK | Hong Kong | $12.4B | +5% | +25% | 28% | 2.2× | -10.3% | +0.1% |
| Halozyme Therapeutics HALO | United States | $11.8B | +62% | +41% | 57% | 8.2× | 2.5% | +39.2% |
| Bio-Techne TECH | United States | $11.4B | +51% | 0% | 22% | 9.4× | 31.3% | +5.5% |
| Kymera Therapeutics KYMR | United States | $11.2B | +53% | +134% | -396% | 101.2× | n/a | n/a |
| BioMarin Pharmaceutical BMRN | United States | $10.9B | +4% | +20% | 19% | 3.9× | 6.5% | +12.0% |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.8B | +30% | 0% | 9% | 3.9× | 7.2% | +2.3% |
| ALTEOGEN 196170.KS | South Korea | $10.3B | -46% | +61% | 53% | 43.0× | 29.8% | +38.5% |
| Vaxcyte PCVX | United States | $10.1B | +21% | n/a | n/a | n/a | n/a | n/a |
| BioNTech SE Sponsored ADR BNTX | United States | $22.8B | -7% | -1% | -38% | 2.0× | 5.7% | +42.6% |
| Krystal Biotech KRYS | United States | $8.92B | -2% | +26% | 48% | 17.1× | 11.9% | +26.0% |
| Genscript Biotech 1548.HK | Hong Kong | $8.81B | +96% | +53% | 12% | 9.9× | 36.5% | +19.8% |
| United Therapeutics UTHR | United States | $24.1B | -1% | +2% | 44% | 6.9× | -0.4% | +16.5% |
| Wuxi Bio 2269.HK | Hong Kong | $25.0B | +43% | +22% | 32% | 7.3× | 21.8% | +30.2% |
| Arrowhead Pharmaceuticals ARWR | United States | $8.22B | -20% | +17% | -34% | 11.9× | n/a | n/a |
| Twist Bioscience TWST | United States | $7.95B | +112% | +19% | -32% | 18.2× | n/a | n/a |
| 10x Genomics TXG | United States | $7.72B | +174% | -4% | -14% | 11.8× | 41.8% | +16.6% |
| Caris Life Sciences CAI | United States | $7.13B | +56% | +85% | 15% | 6.9× | 18.7% | +85.4% |
BridgeBio Pharma has 4 bonds outstanding with $2.50B face value.